<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2017-06-26" updated="2019-12-02">
  <drugbank-id primary="true">DB13862</drugbank-id>
  <name>Magnesium phosphate</name>
  <description/>
  <cas-number>7757-87-1</cas-number>
  <unii>XMK14ETW2D</unii>
  <average-mass>262.858</average-mass>
  <monoisotopic-mass>261.861965694</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as alkaline earth metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.</description>
    <direct-parent>Alkaline earth metal phosphates</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Mixed metal/non-metal compounds</superclass>
    <class>Alkaline earth metal oxoanionic compounds</class>
    <subclass>Alkaline earth metal phosphates</subclass>
    <alternative-parent>Inorganic oxides</alternative-parent>
    <alternative-parent>Inorganic salts</alternative-parent>
    <substituent>Alkaline earth metal phosphate</substituent>
    <substituent>Inorganic oxide</substituent>
    <substituent>Inorganic salt</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002646</drugbank-id>
      <name>Magnesium phosphate dibasic trihydrate</name>
      <unii>HF539G9L3Q</unii>
      <cas-number>7782-75-4</cas-number>
      <inchikey>OKIWLDVQGKRUNR-UHFFFAOYSA-L</inchikey>
      <average-mass>174.33</average-mass>
      <monoisotopic-mass>173.977980988</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002534</drugbank-id>
      <name>Magnesium phosphate pentahydrate</name>
      <unii>453COF7817</unii>
      <cas-number>10233-87-1</cas-number>
      <inchikey>QZYXGKYJDBUYES-UHFFFAOYSA-H</inchikey>
      <average-mass>352.93</average-mass>
      <monoisotopic-mass>351.91478948</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Magnesium phosphate (3:2)</synonym>
    <synonym language="english" coder="">Magnesium phosphate anhydrous</synonym>
    <synonym language="english" coder="">Magnesium phosphate, tribasic</synonym>
    <synonym language="english" coder="">Magnesium phosphate, tribasic, anhydrous</synonym>
    <synonym language="english" coder="">Phosphoric acid, magnesium salt (2:3)</synonym>
    <synonym language="english" coder="">Tertiary magnesium phosphate</synonym>
    <synonym language="english" coder="">Trimagnesium phosphate</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Agents that produce neuromuscular block (indirect)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Substitutes and Perfusion Solutions</category>
      <mesh-id/>
    </category>
    <category>
      <category>Electrolyte Solutions</category>
      <mesh-id/>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>I.V. Solution Additives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Phosphoric Acids</category>
      <mesh-id>D010756</mesh-id>
    </category>
    <category>
      <category>Phosphorus Acids</category>
      <mesh-id>D017976</mesh-id>
    </category>
    <category>
      <category>Phosphorus Compounds</category>
      <mesh-id>D017553</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="B05XA10">
      <level code="B05XA">Electrolyte solutions</level>
      <level code="B05X">I.V. SOLUTION ADDITIVES</level>
      <level code="B05">BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tetracycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Kanamycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Dantrolene is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Rolitetracycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium oxide is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium cation is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Paromomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Ribostamycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Geneticin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin C1a is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neamine is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Arbekacin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06827</drugbank-id>
      <name>Viomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Puromycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium hydroxide is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium trisilicate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium chloride is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium acetate tetrahydrate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium carbonate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium citrate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium glycinate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11230</drugbank-id>
      <name>Magnesium Aluminum Silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Dihydrostreptomycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Hygromycin B is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Sisomicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Plazomicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium silicate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Penimepicycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Dibekacin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Micronomicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium aspartate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Isepamicin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Bekanamycin is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium gluconate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium orotate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium phosphate is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Tetraethylammonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08999</drugbank-id>
      <name>Cyclopentamine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Cyclopentamine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>trimagnesium(2+) ion diphosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>trimagnesium(2+) ion diphosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>262.858</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>261.861965694</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Mg++].[Mg++].[Mg++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>Mg3O8P2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/3Mg.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>GVALZJMUIHGIMD-UHFFFAOYSA-H</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>86.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>11.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>4.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>22847</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Magnesium_phosphate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2106873</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>